United Therapeutics agreed to buy Thymmune Therapeutics in a $300 million regenerative medicine transaction aimed at restoring T-cell function using thymic cell therapies derived from iPSCs. The deal includes $140 million upfront and up to $160 million in milestone payments tied to clinical and regulatory progress. Thymmune’s lead program, THY-100, is in preclinical development for congenital athymia, an ultra-rare condition where infants are born without a functioning thymus, leaving them vulnerable to fatal infections. The company reports that its approach converts human induced pluripotent stem cells into thymic cells that mature in vivo to enable a “neo-thymus,” supporting T-cell development. United Therapeutics said the acquisition complements its broader organ-supply strategy and expands its immunomodulatory pipeline, including the UThymoKidney clinical development program. The transaction also signals continued M&A momentum in cell-based immune restoration and organ-alternative platforms.